Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5795166 | 0.78 | MMP2 (0.50) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL66196 | 0.78 | LMNA (0.59) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL30072318 | 0.77 | HSD11B1 (0.55) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL4328574 | 0.77 | HSD11B1 (0.55) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL548298 | 0.77 | MMP2 (0.54) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL79787 | 0.77 | HSD11B1 (0.55) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL2121770 | 0.77 | HSD11B1 (0.55) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL6916646 | 0.76 | LMNA (0.56) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL6914537 | 0.76 | LMNA (0.56) | CA1CA2MMP2MMP1MMP9 | |
| SCHEMBL6114756 | 0.76 | LMNA (0.56) | CA1CA2MMP2MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115650827-B | Preparation method, intermediate compound and synthesis method for anthracycline derivatives | 戊言医药科技（上海）有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-115651043-A | Preparation method of anthracycline derivative | 戊言医药科技（上海）有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115650827-A | Preparation method, intermediate compound and synthesis method for anthracycline derivatives | 戊言医药科技（上海）有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-111646973-B | Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-19 | — | — | CN | claimed |
| CN-111646973-A | Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-09-11 | — | — | CN | claimed |
| EP-1519932-B1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LTD (GB) | 2007-10-03 | — | — | EP | claimed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | claimed |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CYCLACEL LIMITED (GB) | 2005-09-29 | — | — | US | claimed |
| EP-1519932-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | Cyclacel Limited (GB) | 2005-04-06 | — | — | EP | claimed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | claimed |
| US-6809119-B2 | FOR USE AS AS NEURO-PROTECTIVE AGENTS FOR THERAPY OF CONDITIONS SUCH AS STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMINOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE | WARNER-LAMBERT COMPANY LLC | 2004-10-26 | — | — | US | claimed |
| WO-2004005278-A1 | BISARYLSULFONAMIDE COMPOUNDS AND THEIR USE IN CANCER THERAPY | CYCLACEL LIMITED (GB) | 2004-01-15 | — | — | WO | claimed |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | claimed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | claimed |
| CN-115650827-B | Preparation method, intermediate compound and synthesis method for anthracycline derivatives | 戊言医药科技（上海）有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-115650827-A | Preparation method, intermediate compound and synthesis method for anthracycline derivatives | 戊言医药科技（上海）有限公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-0250096-A1 | Isoxazolone derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-12-23 | — | — | EP | disclosed |
| EP-0219923-A1 | Antibiotic derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-04-29 | — | — | EP | disclosed |
| EP-0191989-A1 | Antibiotic isoxazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | CA1 2057/4885CA2 307/4885MMP2 1433/4885 |
| US-20050215548-A1 | Capable of binding to the oncoprotein HDM2 and modulating the HDM2-dependent regulation of the tumour suppressor p53 and/or E2F transcription factors; e.g. 5-Chloro-4-nitro-thiophene-2-sulfonic acid (4-nitrophenyl)-amide | CCNL2, TP53, MDM2 | CA1 3840/4885CA2 3077/4885MMP2 4206/4885 |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | CA1 549/4885CA2 1297/4885MMP2 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.